Loading organizations...
§ Private Profile · Pittsburgh, PA, USA
Transplant Interface is a company.
Key people at Transplant Interface.
Transplant Interface, LLC operates a platform connecting patients and families with kidney transplant programs nationwide. Its core product centralizes key program details for every US kidney transplant center. This approach simplifies the complex search for appropriate transplant options, offering guidance within this healthcare sector.
CEO Sundaram Hariharan founded the company, drawing on his profound understanding of organ transplantation. His direct experience building and managing robust kidney transplant programs at university hospitals illuminated challenges patients encountered. This insight spurred Transplant Interface's creation, providing a transparent, accessible resource for those navigating the transplant landscape.
Transplant Interface serves patients and families engaged in the kidney transplant journey, empowering them through comprehensive program data. The platform demystifies the selection process by offering transparent, detailed information. Its vision centers on enhancing accessibility and understanding within the transplant ecosystem, ensuring individuals efficiently connect with optimal treatment pathways.
Transplant Connect is a Los Angeles-based company developing the iTransplant platform, a cloud-based software ecosystem for organ, eye, tissue, cellular, and birth tissue donation and transplantation.[1] It serves organ procurement organizations (OPOs), eye banks, tissue banks, transplant centers, hospitals, and research institutions worldwide, solving inefficiencies in donor identification, referral, management, logistics, communications, and analytics by enabling real-time interoperability and automation.[1][2] The platform replaces manual phone-based processes with seamless integrations, like with Cerner EHR, boosting donation rates—handling nearly 75% of U.S. deceased organ donations and driving significant increases where implemented.[1][2]
Acquired and rebranded under InVita Healthcare Technologies, iTransplant remains the world's most advanced donation-transplant management system, configurable for single organizations, networks, or national scales, with proven growth in adoption across the U.S., Europe, Australia, and Canada.[2]
Founded by John Piano, who serves as CEO of Transplant Connect, the company emerged as a pioneer in cloud-based interoperable medical records for the donation-transplant field.[1] The idea stemmed from addressing fragmented, inefficient processes in organ procurement, such as delayed donor referrals via phone, pivotal in a sector where timing saves lives—highlighted by integrations like Cerner Millennium's iReferral engine for near real-time data flow into iTransplant.[1]
Early traction came from partnerships with major EHR providers and OPOs, evolving into the comprehensive iTransplant ecosystem now powering global operations; under InVita, it has scaled to award-winning status with robust analytics and workflow automation, marking key moments like widespread U.S. adoption.[1][2]
Transplant Connect rides the wave of healthcare digitization and interoperability, aligning with trends like EHR integration and AI-driven analytics in a $1T+ global transplant ecosystem strained by organ shortages (e.g., UNOS matches ~46K U.S. transplants yearly).[1][5] Timing is critical amid rising demand—post-COVID policy pushes (e.g., OPTN's 60K transplant goal by 2026) and tech adoption favoring automated workflows over legacy manual systems.[7]
Market forces like regulatory standardization (OPTN/UNOS policies) and data transparency demands amplify its role, influencing the ecosystem by enabling OPOs and centers to optimize performance, reduce delays, and improve patient outcomes, much like how SRTR uses data for program evaluation.[4][7]
Next for Transplant Connect/InVita: deeper AI integrations for predictive analytics, expanded national rollouts (e.g., aligning with OPTN's heart/liver allocation updates), and growth in emerging markets as preservation tech extends organ viability.[5][7] Trends like value-based care and cross-border data sharing will propel iTransplant, potentially capturing more of the underserved tissue/eye segments while influencing policy through outcome data.
Its influence could evolve into the de facto standard, powering a more efficient donation-transplant backbone and accelerating the paradigm shift John Piano championed—ultimately scaling from thousands to tens of thousands of additional lives healed annually.[1]
Key people at Transplant Interface.
